Ken Griffin Genmab A/S Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$26.43 - $32.77 $290,730 - $360,470	11,000 Added 392.86%	13,800 $412,000
Q4 2023 Feb 14, 2024	SELL	$27.94 - $35.44 $2,794 - $3,544	-100 Reduced 3.45%	2,800 $89,000
Q3 2023 Nov 14, 2023	SELL	$35.27 - $42.24 $17,635 - $21,120	-500 Reduced 14.71%	2,900 $102,000
Q2 2023 Aug 14, 2023	SELL	$37.4 - $42.94 $183,260 - $210,406	-4,900 Reduced 59.04%	3,400 $129,000
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $212,768 - $263,642	6,100 Added 277.27%	8,300 $313,000

Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $74,360 - $103,532	2,200 New	2,200 $93,000

241

47.6M

31.3K

38.7K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $16.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.